HCL Research is the first UK site to recruit patient into complex global study  

HCL has recruited its first participant for a commercial vascular clinical trial investigating the efficacy and safety of allo-APZ2-CVU (a stem cell preparation) on wound healing of therapy-resistant, non-healing chronic venous ulcers (CVU).

This is a novel treatment in a first-of-its-kind study for CVU, which are caused by venous insufficiency that severely impairs wound healing in the lower legs. It is a debilitating, painful condition with a high disease burden and infection rate. The standard treatment is compression dressings that help venous return, facilitating healing, but the results are variable, and many ulcers of this kind do not heal even with a good compression regimen.

HCL’s participant will be the first in the UK to receive this treatment.

It’s hoped that the results of this clinical trial will yield a new treatment that can be used for patients with CVU; improving healing potential in ulcers that won’t heal with compression alone and reducing healing time in those that heal only very slowly. This is an outstanding milestone since the study is complex and hard to recruit to, and only opened to recruitment in Dec 2024.

If you would like more information on HCL’s Research work, visit Research | Central London Healthcare